Safeguard Scientifics partner company, Crescendo Bioscience, signed an amended agreement to be acquired by Myriad Genetics (NASDAQ: MYGN). Crescendo offers the first and only multi-biomarker blood test for rheumatoid arthritis, and has the opportunity to help over four million people across the globe to more accurately monitor their condition.

The announcement followed a number of recent exit transactions for Safeguard partner companies Alverix, NuPathe (NASDAQ: PATH) and ThingWorx, together kicking off 2014 with tremendous momentum.

(Visited 423 times, 1 visits today)